BeStock  

Zoetis ZTS

US equityMarket cap rank #616Drug Manufacturers - Specialty & Generic
$79.11 −$1.68 (-2.08%)
Market closed · Nov 20, 8:10 pm ET · Last extended-hours $78.16 -1.20%
Open$81.73
Prev close$80.79
Day range$78.80 – $83.08
Volume6.10M
Market cap$32.14B
P/E (TTM)13.3
Dividend yield2.64%

Fundamentals

Latest reported quarter: Q3, ended Sep 2026

Revenue$2.39B-1.3% YoY
Operating profit$906.00M-3.2% YoY
Net profit$591.00M-18.0% YoY
Diluted EPS$1.44-11.7% YoY
Free cash flow$717.00M-10.2% YoY
Operating cash flow$824.00M

Revenue, last 8 quarters

$2.3BDec '24$2.2BMar '25$2.5BJun '25$2.4BSep '25$2.4BDec '25$2.3BMar '26$2.5BJun '26$2.4BSep '26

Net profit, last 8 quarters

$581.0MDec '24$602.0MMar '25$726.0MJun '25$721.0MSep '25$624.0MDec '25$601.0MMar '26$691.0MJun '26$591.0MSep '26

Diluted EPS by quarter

1.29Dec '241.34Mar '251.63Jun '251.63Sep '251.37Dec '251.42Mar '261.65Jun '261.44Sep '26

Free cash flow by quarter

$689.0MDec '24$337.0MMar '25$459.0MJun '25$798.0MSep '25$689.0MDec '25$291.0MMar '26$538.0MJun '26$717.0MSep '26

Annual revenue

$6.7BFY20$7.8BFY21$8.1BFY22$8.5BFY23$9.3BFY24$9.5BFY25

Profitability & balance sheet

Gross margin71.6%
Operating margin37.7%
Net margin26.4%
Return on equity57.6%
Return on assets16.6%
Return on invested capital20.3%
Current ratio2.35
Liabilities / assets78.1%
Cash & investments$1.53B
Total debt$9.24B
Net cash (debt)-$7.71B
Free cash flow / sales23.5%

Where the revenue comes from

Quarter 2026/Q3

By business line

  • Parasiticides$576.00M 24.1%
  • Vaccines$540.00M 22.6%
  • Dermatology$398.00M 16.6%
  • Anti-infectives$282.00M 11.8%
  • Pain and sedation$200.00M 8.4%
  • Other pharmaceuticals$170.00M 7.1%
  • Animal health diagnostics$128.00M 5.4%
  • Medicated feed additives$68.00M 2.8%
  • Contract manufacturing & human health$29.00M 1.2%

Income statement

Line item 2026 Q3 2026 Q2 2026 Q1 2025 ANNUAL 2025 Q4
Total Revenue as Reported $2.39B $2.47B $2.26B $9.47B $2.37B
Total Operating Revenue $2.39B $2.47B $2.26B $9.47B $2.37B
Cost of Revenue $698.00M $673.00M $641.00M $2.67B $687.00M
Gross Profit $1.69B $1.80B $1.62B $6.80B $1.69B
Operating Expense $787.00M $796.00M $799.00M $3.20B $834.00M
Selling and Admin Expenses $582.00M $592.00M $588.00M $2.38B $608.00M
Research & Development $174.00M $173.00M $180.00M $698.00M $195.00M
Depreciation & Amortization & Depletion $31.00M $31.00M $31.00M $128.00M $31.00M
-Depreciation & Amortization $31.00M $31.00M $31.00M $128.00M $31.00M
Operating Profit $906.00M $999.00M $822.00M $3.60B $852.00M
Net Non-Operating Interest Income (Expense) -$45.00M -$45.00M -$41.00M -$129.00M -$33.00M
Non-Operating Interest Income $17.00M $16.00M $21.00M $93.00M $24.00M
Non-Operating Interest Expense $62.00M $61.00M $62.00M $222.00M $57.00M
Other Income (Expense) -$132.00M -$88.00M -$23.00M -$108.00M -$30.00M
Gain on Sale of Security -$8.00M -$10.00M -$6.00M -$45.00M -$8.00M
Special Income (Charges) -$121.00M -$76.00M -$16.00M -$59.00M -$17.00M
-Less:Restructuring and Mergern & Acquisition $32.00M $77.00M $22.00M $29.00M $17.00M
-Less:Impairment of Capital Assets $78.00M $0.00 – $5.00M $0.00
-Less:Write Off $11.00M $0.00 – $22.00M $0.00
-Gain on Sale Of Business $0.00 $0.00 – -$3.00M $0.00
-Gain on Sale of Property/Plant/Equipment $0.00 $1.00M $6.00M $0.00 $0.00
Other Non-Operating Income (Expenses) -$3.00M -$2.00M -$1.00M -$4.00M -$5.00M
Pretax Profit $729.00M $866.00M $758.00M $3.36B $789.00M
Tax $138.00M $175.00M $157.00M $687.00M $165.00M
Net Profit $591.00M $691.00M $601.00M $2.67B $624.00M
Profit from Continuing Operations $591.00M $691.00M $601.00M $2.67B $624.00M
Minority Interests $0.00 $0.00 $0.00 $0.00 $0.00
Net Income to Parent Company $591.00M $691.00M $601.00M $2.67B $624.00M
Net Income to Common Stockholders $591.00M $691.00M $601.00M $2.67B $624.00M
Basic EPS $1.44 $1.65 $1.42 $6.03 $1.38
Diluted EPS $1.44 $1.65 $1.42 $6.02 $1.37
Dividend Per Share $0.53 $0.53 $0.53 $2.00 $0.50

Balance sheet

Line item 2026 Q3 2026 Q2 2026 Q1 2025 ANNUAL 2025 Q4
Total Assets $15.09B $15.08B $15.15B $15.47B $15.47B
Total Current Assets $6.29B $6.36B $6.47B $6.77B $6.77B
Cash and Cash Equivalents & Short-Term Investments $1.53B $1.67B $1.94B $2.31B $2.31B
-Cash and Cash Equivalents $1.33B $1.47B $1.94B $2.31B $2.31B
-Short Term Investments $200.00M $200.00M – – –
Receivables $1.69B $1.57B $1.51B $1.59B $1.59B
-Accounts Receivable $1.69B $1.57B $1.51B $1.59B $1.59B
Inventory $2.54B $2.57B $2.55B $2.43B $2.43B
Restricted Cash $2.00M $3.00M $1.00M $2.00M $2.00M
Other Current Assets $532.00M $535.00M $477.00M $436.00M $436.00M
Total Non-Current Assets $8.80B $8.72B $8.68B $8.70B $8.70B
Net PPE $4.05B $4.03B $4.00B $3.97B $3.97B
-Gross PPE $4.05B $4.03B $4.00B $6.89B $6.89B
Goodwill and Other Intangible Assets $3.74B $3.69B $3.74B $3.77B $3.77B
-Goodwill $2.89B $2.77B $2.78B $2.77B $2.77B
-Other Intangible Assets $850.00M $918.00M $959.00M $998.00M $998.00M
Non-Current Deferred Assets $608.00M $617.00M $591.00M $637.00M $637.00M
Other Non-Current Assets $398.00M $384.00M $351.00M $328.00M $328.00M
Total Liabilities $11.79B $11.93B $11.92B $12.14B $12.14B
Total Current Liabilities $2.68B $2.06B $2.05B $2.24B $2.24B
Payables $620.00M $811.00M $942.00M $866.00M $866.00M
-Accounts Payable $419.00M $452.00M $507.00M $487.00M $487.00M
-Total Tax Payable $201.00M $138.00M $211.00M $147.00M $147.00M
-Dividends Payable $0.00 $221.00M $224.00M $232.00M $232.00M
Current Accrued Expenses $899.00M $856.00M $751.00M $852.00M $852.00M
Short-Term Debt and Capital Lease Obligation $750.00M – – – –
-Current Debt $750.00M – – – –
Other Current Liabilities $113.00M $125.00M $121.00M $107.00M $107.00M
Total Non-Current Liabilities $9.10B $9.87B $9.87B $9.90B $9.90B
Long Term Accounts Payable and Other Payables $295.00M $288.00M $281.00M $276.00M $276.00M
Long Term Debt and Capital Lease Obligation $8.49B $9.24B $9.24B $9.24B $9.24B
-Long Term Debt $8.30B $9.05B $9.05B $9.04B $9.04B
-Long Term Capital Lease Obligation $188.00M $190.00M $193.00M $196.00M $196.00M
Non-Current Deferred Liabilities $104.00M $122.00M $130.00M $139.00M $139.00M
Other Non-Current Liabilities $217.00M $220.00M $219.00M $248.00M $248.00M
Total Equity $3.30B $3.15B $3.23B $3.33B $3.33B
Stockholders' Equity $3.30B $3.15B $3.23B $3.33B $3.33B
Capital Stock $5.00M $5.00M $5.00M $5.00M $5.00M
-Common Stock $5.00M $5.00M $5.00M $5.00M $5.00M
Additional Paid-In Capital $1.16B $1.13B $1.11B $1.10B $1.10B
Retained Earnings $15.25B $14.65B $14.18B $13.74B $13.74B
Less: Treasury Stock -$12.35B -$11.85B -$11.29B -$10.69B -$10.69B
Gains/Losses Not Affecting Retained Earnings -$755.00M -$796.00M -$772.00M -$834.00M -$834.00M
Minority Interests $0.00 $0.00 $0.00 $0.00 $0.00
-Accumulated Depreciation – – – -$2.93B -$2.93B

Cash flow

Line item 2026 Q3 2026 Q2 2026 Q1 2025 ANNUAL 2025 Q4
Operating Cash Flow $824.00M $655.00M $401.00M $2.90B $848.00M
Net cash flow from continuing operations $824.00M $655.00M $401.00M $2.90B $848.00M
Net Income from Continuing Operations $591.00M $691.00M $601.00M $2.67B $624.00M
Gain/Loss from Continuing Operations $0.00 $2.00M -$9.00M $14.00M $0.00
Depreciation & Depletion & Amortization $132.00M $119.00M $119.00M $487.00M $114.00M
Deferred Tax -$12.00M -$33.00M $34.00M -$52.00M -$48.00M
Change in Working Capital -$40.00M -$158.00M -$385.00M -$408.00M $119.00M
-Change in Receivables -$119.00M -$66.00M -$106.00M -$236.00M -$46.00M
-Change in Inventory -$6.00M -$23.00M -$114.00M -$199.00M -$17.00M
-Change in Payables and Accrued Expense -$37.00M -$53.00M $62.00M $46.00M $30.00M
-Change in Other Current Assets -$16.00M -$92.00M -$66.00M -$165.00M $43.00M
-Change in Other Current Liabilities $69.00M $142.00M -$234.00M $85.00M $84.00M
-Change In Other Working Capital $69.00M -$66.00M $73.00M $61.00M $25.00M
Net cash flow from investing -$262.00M -$300.00M -$87.00M -$748.00M -$165.00M
Net Cash Flow from Continuing Investing Activities -$262.00M -$300.00M -$87.00M -$748.00M -$165.00M
Capital Expenditure -$107.00M -$117.00M -$110.00M -$621.00M -$159.00M
Net Business Purchase and Sale -$155.00M – – -$28.00M -$14.00M
Net Investment Purchase and Sale $0.00 -$186.00M $14.00M -$100.00M $10.00M
Net Other Investing Changes $0.00 $3.00M $9.00M $1.00M -$2.00M
Financing Cash Flow -$718.00M -$813.00M -$840.00M -$1.87B -$495.00M
Net Cash Flow from Continuing Financing Activities -$718.00M -$813.00M -$840.00M -$1.87B -$495.00M
Net Common Stock Issuance -$500.00M -$584.00M -$606.00M -$3.24B -$2.06B
Cash Dividends Paid -$219.00M -$223.00M -$224.00M -$889.00M -$220.00M
Proceeds from Stock Option Exercised $0.00 -$5.00M -$7.00M -$11.00M $1.00M
Net Other Financing Charges $1.00M -$1.00M -$3.00M -$233.00M -$216.00M
Ending Cash Balance $1.33B $1.48B $1.94B $2.31B $2.31B
Net Change in Cash -$156.00M -$458.00M -$526.00M $286.00M $188.00M
Beginning Cash Balance $1.48B $1.94B $2.45B $1.99B $2.27B
Effect of Exchange Rate Changes $13.00M -$7.00M $17.00M $39.00M -$19.00M
Free Cash Flow $717.00M $538.00M $291.00M $2.28B $689.00M
Other Non-Cash Items – -$5.00M $3.00M -$8.00M -$1.00M
Net Issuance Payments Of Debt – – – $2.50B $2.00B

Discussion

No comments yet — be the first to weigh in on ZTS.

Sign in to join the discussion.

Scroll to Top